Last $24.23 USD
Change Today +1.15 / 4.98%
Volume 442.8K
SPNC On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $31.94
52 Week Low
09/4/13 - $15.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; and coronary atherectomy and thrombectomy, which are aspiration and cardiac laser catheters for the treatment of blockages in the heart. Its primary vascular intervention products include the Turbo Elite and Turbo-Tandem laser catheters and the TAPAS drug delivery catheters for peripheral atherectomy; crossing catheters, such as the Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, GlideLight, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

575 Employees
Last Reported Date: 02/28/14
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $526.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $311.6K
Chief Operating Officer
Total Annual Compensation: $256.4K
Senior Vice President of Lead Management Sale...
Total Annual Compensation: $265.7K
Senior Vice President of Global Human Resourc...
Total Annual Compensation: $121.2K
Compensation as of Fiscal Year 2012.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Announces FDA Clearance for Mechanical Lead Extraction Devices

The Spectranetics Corporation announced FDA clearance of two new mechanical lead extraction platforms that expand physicians' options for safe removal of cardiac leads. Each incorporates innovative designs for mechanical extraction aimed at providing total lead management solutions. The TightRail rotating mechanical sheath platform combines unprecedented shaft flexibility and column strength to help physicians safely navigate the vasculature during cardiac lead extraction procedures. An advanced forward-facing dilating blade remains shielded until activated. The tip feature rotates in both directions for efficient dilation. The physician controls when the blade is exposed, for procedural safety. The SightRail manual dilator sheath platform features visual indicators that show bevel orientation and tip alignment, supplementing fluoroscopy as a means to determine position and orientation. A longer inner sheath gives physicians improved ability to grip and manipulate the device, especially when advancing and rotating. The SightRail sheath set has also received CE mark approval for use in Europe.

Spectranetics Provides Earnings Guidance for the First Quarter of 2014; Revises Earnings Guidance for the Full Year of 2014

Spectranetics provided earnings guidance for the fourth quarter and revised earnings guidance for the full year of 2014. For the quarter, the company expects preliminary revenue of $39.6 million. Loss for the quarter is see in the range of $0.14 to $0.15 per share. For the year 2014, the company is targeting revenue in the range of $171.5 million to $174 million, down from its prior outlook of $177.5 million to $180 million. Loss is expected in the range of $0.18 to $0.23, wider than previous projections of a loss of $0.07 to $0.12 per share.

Spectranetics Announces Early Success of EXCITE ISR

The Spectranetics Corporation announced early success of the EXCITE ISR clinical trial, achieving highly significant statistical superiority in both safety and efficacy. Notably, this superior outcome was achieved without any borrowing from the PATENT registry. Based on this result, Spectranetics has concluded enrollment in the EXCITE ISR trial and will submit the 510(k) application to the Food and Drug Administration (FDA). FDA review of a 510(k) application with clinical data takes an average of five months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $24.23 USD +1.15

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $24.64 USD +0.16
Cardiovascular Systems Inc $26.08 USD -0.09
CryoLife Inc $9.89 USD +0.08
Endologix Inc $12.43 USD +0.28
Vascular Solutions Inc $23.85 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 5.3x
Price/Cash Flow 1,885.9x
TEV/Sales 5.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at